MXPA05011110A - Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. - Google Patents

Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.

Info

Publication number
MXPA05011110A
MXPA05011110A MXPA05011110A MXPA05011110A MXPA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A MX PA05011110 A MXPA05011110 A MX PA05011110A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
prevention
treatment
meningococcal disease
novel immunogenic
Prior art date
Application number
MXPA05011110A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin J Metcalf
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MXPA05011110A publication Critical patent/MXPA05011110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA05011110A 2003-04-16 2004-04-16 Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. MXPA05011110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46316103P 2003-04-16 2003-04-16
PCT/US2004/011901 WO2004094596A2 (en) 2003-04-16 2004-04-16 Novel immunogenic compositions for the prevention and treatment of meningococcal disease

Publications (1)

Publication Number Publication Date
MXPA05011110A true MXPA05011110A (es) 2006-01-24

Family

ID=33310752

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011110A MXPA05011110A (es) 2003-04-16 2004-04-16 Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.

Country Status (11)

Country Link
US (5) US20070253964A1 (enExample)
EP (1) EP1618185A4 (enExample)
JP (1) JP2006525330A (enExample)
KR (1) KR20060019515A (enExample)
CN (1) CN1867354A (enExample)
AU (2) AU2004233012A1 (enExample)
BR (1) BRPI0409459A (enExample)
CA (1) CA2522751A1 (enExample)
CO (1) CO5700785A2 (enExample)
MX (1) MXPA05011110A (enExample)
WO (1) WO2004094596A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1093517T3 (da) 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
NZ515935A (en) 1999-05-19 2004-01-30 Chiron S Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP2275553B1 (en) 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
JP4763210B2 (ja) 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP2425856A1 (en) 2005-04-08 2012-03-07 Wyeth LLC Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
WO2007042326A2 (en) * 2005-10-14 2007-04-19 Intercell Ag Neisseria meningitidis antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
AU2007277081B2 (en) * 2006-07-27 2014-02-06 Wyeth Llc High-cell density fed-batch fermentation process for producing recombinant protein
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
GB0819633D0 (en) * 2008-10-25 2008-12-03 Isis Innovation Composition
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011110634A1 (en) * 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Vaccine composition
BR112012027315B1 (pt) * 2010-05-14 2021-08-17 Baxalta Incorporated Polipeptídeo, composição, molécula de ácido nucleico, vetor, microrganismo transgênico, processo de produção de um polipeptídeo, vacina combinada, e, uso de uma composição ou de uma vacina combinada
AU2011262346B2 (en) 2010-06-04 2014-12-11 Wyeth Llc Streptococcus pneumoniae vaccine formulations
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
DK2608805T4 (da) 2010-08-23 2025-06-30 Wyeth Llc STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
RU2546873C2 (ru) * 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
US10596246B2 (en) 2011-12-29 2020-03-24 Glaxosmithkline Biological Sa Adjuvanted combinations of meningococcal factor H binding proteins
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
WO2013186753A1 (en) 2012-06-14 2013-12-19 Novartis Ag Vaccines for serogroup x meningococcus
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) * 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SI3110442T1 (sl) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals S.A. Modificirani meningokokni fHbp polipeptidi
MX391027B (es) * 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
GB202016604D0 (en) * 2020-10-20 2020-12-02 Univ Of Oxford Compositions and methods for inducing an immune response
CN113372571A (zh) * 2021-07-05 2021-09-10 云南紫辰集团生物科技有限公司 黄腐酸钾干粉的生产工艺
CN114295845B (zh) * 2021-12-01 2024-07-19 柏荣诊断产品（上海）有限公司 一种高特异性透散射一体法降钙素原胶乳比浊检测试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466829A (en) * 1892-01-12 Carpet-stretcher
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4980289A (en) * 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5124263A (en) * 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
FR2708622B1 (fr) * 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US5739118A (en) * 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
DE19723095C2 (de) * 1997-06-02 2001-08-23 Siemens Ag Bildrekonstruktionsverfahren für einen Computertomographen
JP4290875B2 (ja) * 1998-02-03 2009-07-08 センター フォア ディズィーズ コントロール アンド プリヴェンション 組換え脂質化ＰｓａＡタンパク質、調製法および使用
DK1093517T3 (da) * 1998-05-01 2008-06-23 Novartis Vaccines & Diagnostic Neisseria-meningitidis-antigener og præparater
MXPA01003228A (es) * 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
WO2003025132A2 (en) * 2001-09-14 2003-03-27 Invitrogen Corporation Dna polymerases and mutants thereof
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741

Also Published As

Publication number Publication date
AU2010200892A1 (en) 2010-04-01
KR20060019515A (ko) 2006-03-03
US20070082007A1 (en) 2007-04-12
EP1618185A2 (en) 2006-01-25
US20090202593A1 (en) 2009-08-13
WO2004094596A2 (en) 2004-11-04
EP1618185A4 (en) 2009-05-27
US20070082866A1 (en) 2007-04-12
BRPI0409459A (pt) 2006-05-02
US20070253964A1 (en) 2007-11-01
AU2004233012A1 (en) 2004-11-04
JP2006525330A (ja) 2006-11-09
WO2004094596A8 (en) 2006-06-15
CO5700785A2 (es) 2006-11-30
US20070082006A1 (en) 2007-04-12
CN1867354A (zh) 2006-11-22
CA2522751A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
MXPA05011110A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
WO2003063766A3 (en) Novel immunogenic compositions for the prevention and treatment of meningococcal disease
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
NZ601538A (en) Vaccine compositions comprising a mutated factor h binding protein
MXPA01011047A (es) Secuencias genomicas de neisseria y metodos para su uso.
DE60028970D1 (de) An her2 bindende peptidverbindungen
WO2007062107A3 (en) Immunostimulatory oligoribonucleotides
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
RU2007139915A (ru) Haemophilus influenzae типа в
NZ595063A (en) Polypeptides from neisseria meningitidis
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
JP2008508859A5 (enExample)
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
BR0015961A (pt) Antìgeno de neisseria de 85kda
TW200514569A (en) Vaccine composition
MA27699A1 (fr) Vaccin contre vhc
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
ATE420658T1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
WO2004074491A3 (en) Expression in plants of antibodies against enterotoxigenic escherichia coli
MA27474A1 (fr) Vaccin
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
WO2005117956A3 (en) Neisserial vaccines
WO2008001045A8 (en) Members of the glycoside hydrolase family 31 family of proteins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal